The Trio N-Terminal RhoGEF Domain Inhibitor, ITX3, also referenced under CAS 347323-96-0, controls the biological activity of Trio N-Terminal RhoGEF Domain. This small molecule/inhibitor is primarily used for Cell Structure applications.
別名:
Trio N-Terminal RhoGEF Domain Inhibitor, ITX3, (2E)-(-2-((2,5-Dimethyl-1-phenyl-pyrrol-3-yl)methylene)thiazolo[3,2-a]benzimidazol-1-one, Inhibitor of Ttrio e Xchange 3
A cell-permeable thiazolo-benzimidazolone compound that inhibits Trio N-terminal RhoGEF domain- (TrioN) mediated RhoG activation (IC50 = 76 µM) and effectively reduces cellular Rac activation (by 80% with 50 µM ITX3) caused by TrioN, but not GEF337 (RhoA GEF), Tiam1 (Rac GEF), or Vav2 (Rac1/RhoA/Cdc42 GEF), overexpression in HEK293T cells. Culture treatment of ITX at 100 µM is shown to reduce NGF-induced neurite outgrowth of rat PC12 pheochromocytoma cells by 50% and block the formation of multinucleated myotubes by 78% in C2C12 mouse myoblasts cultures induced for differentiation, while the differentiation-associated Myogenin and Troponin T expressions in Trio knock-down C2C12 cells are not affected by ITX at the same concentration.
包装
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
再構成
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
その他情報
Bouquier, N., et al. 2009. Chem. Biol.16, 657.
法的情報
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany